This is the exact issue which has concerned me from the start. I have a decent long position, but I can't help wondering why Gilead hasn't tried to buy the company now rather than after phase 3 when it will cost A LOT more. I would think Gilead would want to buy cheap and sunset PRO140 to protect their revenues from HAART. Makes me wonder if Gilead has better info than we do, i.e. perhaps doesn't expect the FDA to approve for whatever reason. Any thoughts?
Market Data 
Markets 
AI
